Dataset Information

Intratumoral delivery of EpCAM-CD3-Fc bispecific antibody with IL-12 and GM-CSF mRNA-lipid nanoparticles (LNPs) blocks both local and distal tumor growth

ABSTRACT: Intratumoral delivery of mRNA–lipid nanoparticles (LNPs)–encoded bispecific antibodies and immunomodulatory proteins is a promising strategy for tumor eradication, offering potent local activity with limited toxicity and minimal systemic exposure. In this study, we evaluated two combinations of four immunostimulatory mRNAs and found that intratumoral administration of IL-2 and GM-CSF mRNA–LNPs together with EpCAM-CD3-Fc mRNA–LNP in OVCAR-5 and PC3 xenograft models significantly blocked the growth of not only local, treated tumors but also distant, untreated lesions. In PC3 tumors, enhanced local and systemic antitumor activity of the combination treatment was associated with activation of T-cell–related pathways, as revealed by RNA-seq analysis. Key effector genes—including perforin (PRF1), granzyme H (GZMH), CD3E, CD3D, HLA-DPA1, among others—were upregulated following treatment with the bispecific antibody plus immunomodulator mRNA–LNPs, providing mechanistic support for the observed efficacy in both local and distant tumors. Collectively, these data demonstrate that intratumoral delivery of EpCAM-CD3-Fc together with IL-2 and GM-CSF mRNA–LNPs represents a promising approach for future clinical investigation.

ORGANISM(S): Mus musculus

PROVIDER: GSE314273 | GEO | 2026/09/04

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:Background: T cell engaging therapies are commonly accompanied by excessive cytokine production and risk of cytokine release syndrome (CRS). Intriguingly, CRS risk with CD3-engaging bispecific antibody (BSP) is primarily limited to the first dose, termed the first-dose effect. Mechanisms underlying this effect remain unknown. CD3 bispecific induces cytokine cascade via T cell triggering and bystander cells. We hypothesize that distinct T cell biology between doses drives the first-dose effect. Methods: We used the Re-directed T Cell Cytotoxicity (RTCC) assay to assess tumor killing and cytokine production by human donor T cells after initial versus subsequent CD3/CD20 BSP treatment. After confirming the first-dose effect in the experimental system containing only T cells and target tumor cells, we employed 10x Genomics single cell multi-omics to study the molecular mechanisms.Results: Compared with initial treatment, subsequent treatment exhibited lower cytokine levels and comparable tumor killing. Single cell multi-omics unveiled distinct T cell biology. In initial treatment, T effector memory (Tem) cells are the primary cells that respond to CD3 bispecific antibody stimulus by producing moderate levels of cytolytic and high levels of cytokine gene transcription. In the subsequent treatment, a new population of high TCF7 expressing central memory CD8+ cells (CD8-Tcm-TCF7), possibly originated from stimulated naive T cells, are the primary responding cells that produce a shifted balance with high level of the cytolytic gene transcription (GZMB) and low level of cytokine gene transcription (TNF-alpha and INF-gamma). Dasatinib co-treatment during initial treatment eliminated cytolytic activity and cytokine production, allowing uncompromised tumor killing and reduced cytokine production upon re-challenge. Conclusions: The distinct T cell populations that respond to first and subsequent CD3 bispecific treatment offer an explanation to the first-dose effect, wherein the risk of CRS associated with CD3 bispecific treatment is mainly limited to the initial dose. Furthermore, our work suggests that tumor killing capacity and cytokine production of T cells could be uncoupled, as demonstrated here by utilizing different T cell populations as effector cells. These findings could be further explored for designing mechanism-based strategies to mitigate the risk of CRS.

Dataset Information

Intratumoral delivery of EpCAM-CD3-Fc bispecific antibody with IL-12 and GM-CSF mRNA-lipid nanoparticles (LNPs) blocks both local and distal tumor growth

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets